TMCnet News
Global Colorectal Cancer Diagnostics & Therapeutics Market Growth of 1-5% CAGR by 2020 - Analysis, Technologies & Forecasts Report 2015-2020 - Key Vendors: Alere, Fujirebio, Metabiomics - Research and MarketsResearch and Markets has announced the addition of the "Global Colorectal Cancer Diagnostics & Therapeutics Market - Segmented by diagnosis, technology and geography (2015 - 2020)" report to their offering. The global colorectal cancer diagnostics and therapeutics market is expected to grow at a compound annual growth rate (CAGR) of 1-5% during the forecast period of 2015-2020. The market is valued at USD 14,143 million, as per 2015. The CRC pipeline is highly robust, with a number of potential drug candidates present across the various phases of clinical development. With nearly 400 active pipeline molecules, the majority of the investigational drug candidates are being evaluated for the treatment of CRC in advanced stages, either as first-line or as second-line therapies. The current investigational pipeline candidates include new combination therapies and targeted therapies, as well as promising immunotherapies and chemotherapy drug candidaes. Along with these active progressing pipeline molecules, the pipeline also includes nearly 180 molecules that are either inactive or discontinued. The global colorectal cancer diagnostics and therapeutics market is segmented on the basis of:
Companies Mentioned:
Report Structure: 1. Introduction 2 Executive summary 3. Market overview 4. Portors five force analysis 5. Market segmentation 6.Competitive Landscape 7. Company profiles 8Appendix For more information visit http://www.researchandmarkets.com/research/lzdj73/global_colorectal View source version on businesswire.com: http://www.businesswire.com/news/home/20160722005323/en/ |
